Agenus Appoints Ulf Wiinberg to Board of Directors

-Serves on boards of Avillion, Hansa Medical, Nestle Health Science, UCB SA -

LEXINGTON, Mass.--()--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Ulf Wiinberg to the Company’s Board of Directors. Ulf has more than 30 years of pharmaceutical experience and currently serves on the boards of multiple global drug development companies.

“Ulf’s extensive industry experience in leadership roles, along with his unique perspective and insight of the global biopharmaceutical industry, will be invaluable as we advance our pipeline of immuno-oncology product candidates, including antibodies and vaccines, through clinical development, partnership activities and commercialization,” said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.

Mr. Wiinberg joins the board as an independent director with almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck A/S, a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several healthcare industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP (Chairman), a London-based drug development company, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Nestle Health Science.

“Agenus’ long pedigree in immunology and cancer along with its extensive and diverse pipeline and platform technologies has the potential to transform patient care and outcomes,” Mr. Wiinberg said. “I look forward to providing my knowledge and support to help the Company and its outstanding team reach its strategic objectives at this critical stage of growth.”

About Agenus

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach to target identification and validation, and for the discovery, development and manufacturing of monoclonal antibodies. The Company’s broad portfolio of novel checkpoint and other monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. Agenus’ heat shock protein-based vaccine, Prophage™, has successfully completed Phase 2 trials in newly-diagnosed glioblastoma. The Company has formed collaborations with Merck and Incyte to discover and develop multiple antibodies. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding plans for clinical development, partnership activities and potential commercialization of any product candidates. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or annual report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contacts

Agenus
Agenus Inc.
Michelle Linn, 774-696-3803
michelle.linn@agenusbio.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com

Contacts

Agenus
Agenus Inc.
Michelle Linn, 774-696-3803
michelle.linn@agenusbio.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com